The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.
The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.
Pope Leo XIV departed for a 12-day trip through Uruguay, Argentina, and Peru on Friday, his first major foreign visit as pope and a return to the continent where he spent two decades as a missionary, coming just three weeks after undergoing lung cancer surgery.
A new Mayo Clinic study reveals that checkpoint immunotherapy may reorganize the immune environment within lymph nodes after melanoma has spread to them. The research demonstrates how the treatment restructures immune cell interactions in affected lymph nodes.
Researchers at Fox Chase Cancer Center discovered that blocking the anoctamin 6 (ANO6) protein can slow pancreatic tumor growth and reduce immune suppression in preclinical trials. The study reveals that cancer-associated fibroblasts transfer membrane lipids to cancer cells through ANO6-dependent trogocytosis, fueling tumor progression.
A Stanford Medicine study found that cancer survivors diagnosed with mental health disorders two to five years after their cancer diagnosis had a 119% higher rate of death from cancer compared to patients without documented mental disorders during the same period. The research highlights a previously overlooked period of vulnerability for cancer survivors.
Northwestern Medicine scientists have demonstrated a novel liquid biopsy technique that can measure cancer burden and reveal molecular characteristics of small cell lung cancer, according to a study published in the Journal of Clinical Investigation. The approach could eventually allow for better tracking and monitoring of this aggressive cancer type.
Researchers at Roswell Park Comprehensive Cancer Center have discovered that hormone-blocking therapies commonly used to treat prostate cancer temporarily activate the body's immune response, revealing a critical window for boosting immunotherapy effectiveness.
A research team at KAIST has developed GB2Ab, a therapeutic antibody candidate that blocks signals responsible for appetite suppression, weight loss, and muscle wasting in cancer cachexia. The antibody successfully reversed weight and muscle loss in mouse models.
A study led by Adelaide University and SAHMRI provides the first direct evidence that asciminib, a targeted therapy for chronic myeloid leukemia, can rapidly and consistently suppress the cancer-driving protein within one week, offering a more effective and better-tolerated treatment option for CML patients.
A phase 1/2 trial led by Roswell Park Comprehensive Cancer Center found that combining bevacizumab (Avastin) and pazopanib (Votrient) significantly extends both progression-free and overall survival in patients with metastatic clear-cell renal cell carcinoma, the most common type of kidney cancer. The study established a safe dosing regimen and demonstrated promising antitumor activity in treatment-naive patients.
Preclinical research demonstrates that macrophages can be programmed to fight solid cancer tumors, offering a potential new immunotherapy approach. The development comes as cancer kills one person every 50 seconds in the U.S., with some cancers continuing to resist current treatments.
Researchers have developed a gradient-driven microfluidic lab-on-chip platform called GradientScreen that can predict which drug combinations will be most effective for treating pediatric acute lymphoblastic leukemia. The technology screens ratiometric drug combinations to enable precision oncology approaches for the disease, which affects more than 3,500 children annually in the U.S.
An analysis published in CANCER reveals a broad shift away from overtreatment of low-risk prostate cancer in the United States, with more men choosing surveillance over immediate treatment in response to concerns about overdiagnosis and overtreatment.
AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.
Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.
Clinical trial results show 29.2% of patients with advanced melanoma experienced complete tumor disappearance on scans after receiving lifileucel TIL therapy combined with pembrolizumab immune checkpoint inhibitor as first-line treatment. The IOV-COM-202 trial demonstrates significant efficacy for this combination immunotherapy approach.
Results from France's early-access program demonstrate that PSMA-targeted radiopharmaceutical therapy Lu-PSMA-617 is safe and effective for patients with metastatic castration-resistant prostate cancer in routine clinical practice, confirming findings from controlled trials.
Bristol Myers Squibb and partner SystImmune announced that their experimental breast cancer treatment izalontamab brengitecan reduced the risk of disease progression or death by 59% compared to standard chemotherapy in patients with advanced HR+/HER2- breast cancer in the phase 3 PANKU-Breast01 study. The late-breaking results are being presented at ESMO 2026.
Roche has entered into a global license and collaboration agreement with Zymeworks for ZW209, a trispecific T cell engager targeting DLL3 for lung cancer treatment. The deal includes $55 million upfront, up to $718 million in milestone payments, and tiered royalties on future sales.
Johnson & Johnson reported promising results from an early-stage clinical trial of its experimental oral prostate cancer treatment JNJ-6143, with 77% of patients with advanced prostate cancer experiencing significant drops in PSA levels after treatment. The trial involved patients who had undergone multiple prior treatments.
A novel diagnostic test could enable doctors to identify which prostate cancer patients would benefit from more intensive treatment with drugs like abiraterone, while sparing others from unnecessary side effects. The test aims to address the challenge of tailoring treatment for prostate cancer, which affects over 1 million men worldwide and behaves differently in each patient.
A new study published in Blood Journal reveals that chronic lymphocytic leukemia (CLL) cells can switch between different survival signals to evade treatment, helping explain why therapies work for some patients but develop resistance in others. The research identifies how cancer cells alternate between low and high basal signaling states through TLR9 activation.
An international research team led by RCSI University of Medicine and Health Sciences and The Institute of Cancer Research, London has identified potential new treatment approaches for microsatellite-stable colorectal cancer, the most common type in Ireland. The study provides a roadmap for repurposing existing drugs to treat this cancer subtype.
A new analysis of a phase 3 clinical trial presented at ESMO 2026 found that daraxonrasib, a recently approved targeted therapy, improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer. The drug represents the biggest advance in decades against the notoriously hard-to-treat disease.
Researchers have developed RPT04402, a molecular glue that stabilizes protein phosphatase 2A (PP2A), a key regulator of cell signaling pathways frequently disrupted in tumors. The compound shows promise in inhibiting non-small cell lung cancer and uterine cancer development.
The mRNA-based personalized cancer vaccine combined with Keytruda reduced the risk of melanoma death or recurrence by 42% in a late-stage trial, though leaked data triggered a sell-off in Moderna shares despite meeting expectations.
UCLA investigators have created MAESTRO, an artificial intelligence platform that uses large language models to analyze scientific knowledge and identify promising drug combinations to overcome treatment resistance in cancer. The platform was described in the journal Advanced Science.
A University of Pittsburgh study published in JAMA Otolaryngology–Head & Neck Surgery found that head and neck cancer patients who participated in multidisciplinary survivorship clinics earlier experienced better survival rates and lower cancer recurrence compared to those who began survivorship care later.
Coherence Neuro has raised $45 million in funding from OpenAI's venture capital arm and Founders Fund to develop a brain implant designed to detect and treat cancer. The coin-sized device monitors tumor activity through neural signals.
The FDA has granted accelerated approval to dostarlimab-gxly (Jemperli) as monotherapy for adults with previously untreated stage II or III locally advanced rectal cancer with dMMR or MSI-H status, based on interim phase 2 AZUR-1 trial results. This marks a first-in-class approval in this specific type of rectal cancer.
Armed Cell Therapeutics, a Belgian startup chaired by former Galapagos CEO Paul Stoffels, has acquired the CAR-T cell therapy assets that Lakefront Biotherapeutics (formerly Galapagos) divested during its strategic overhaul. The deal allows Stoffels to continue developing the cancer cell therapies he had championed during his tenure at Galapagos.
The FDA approved TUKYSA (tucatinib) in combination with trastuzumab and pertuzumab as a chemotherapy-free maintenance treatment for adults with HER2-positive metastatic breast cancer. The approval was supported by data showing more than 50% improvement in median progression-free survival.
The NHS has started using a new rapid genetic test that can diagnose brain tumours in approximately two hours while patients are still on the operating table, compared to the previous wait of up to eight weeks. The test uses DNA analysis to identify which type of tumour a patient has, allowing doctors to begin treatment much sooner.
The FDA has approved Lyrfigtu (lirafugratinib) as a second-line treatment for cholangiocarcinoma (bile duct cancer) with FGFR2 fusion or other rearrangements. The drug demonstrated a 46% confirmed objective response rate and median duration of response of 11.8 months in clinical trials.
Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.
Roche announced that its T-cell engager Lunsumio successfully met the primary endpoint in a confirmatory phase 3 trial for earlier-line follicular lymphoma treatment. The company is now pursuing a label expansion for the drug based on these positive results.
England's NHS will provide AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for aggressive breast cancer after the drug was previously rejected twice. The approval follows an agreement reached with the companies.
The IMpower030 trial showed that adding perioperative atezolizumab to platinum-based chemotherapy nearly doubled median event-free survival in patients with stage IIB-IIIB resectable non-small cell lung cancer without EGFR mutations, but the drug missed its primary endpoint.
The FDA has approved photodynamic therapy as a treatment option for superficial basal cell carcinoma, the most common form of skin cancer. The approach is particularly suited for cosmetically sensitive areas of the body.
A large international real-world study found that a multimodal explainable AI decision support tool outperformed established biomarkers for predicting immunotherapy outcomes in non-small cell lung cancer and improved physician decision-making.
The US Food and Drug Administration has granted expanded accelerated approval for sevabertinib as a frontline treatment option for patients with HER2-mutant advanced non-small cell lung cancer, with nursing management focusing on diarrhea monitoring.
AbbVie announced positive Phase 3 results for etentamig, a dual-acting T cell engager for multiple myeloma, showing survival benefits with a cleaner safety profile compared to competing BCMA-targeting therapies from Johnson & Johnson, Pfizer and Regeneron. The company is seeking to enter the crowded multiple myeloma treatment market.
The Kenyan government has reached an agreement with US pharmaceutical company Pfizer that will reduce the cost of cancer medications by more than sevenfold, according to President William Ruto. The deal is expected to significantly lower treatment costs for cancer patients across the country.
BioNTech ended a mid-stage study of its experimental mRNA cancer vaccine after an independent committee determined the treatment was unlikely to help colorectal cancer patients live longer.
Innovent Biologics has initiated a registrational phase 3 study evaluating IBI363, a PD-1/IL-2α bispecific fusion protein, combined with bevacizumab in 550 patients with treatment-refractory colorectal cancer.
The FDA has approved Zenbexus (iberdomide) for multiple myeloma treatment, marking the first approval in the novel CELMoD drug class that uses targeted protein degradation. Bristol Myers Squibb acquired the therapy through its Celgene acquisition and is positioning it as a successor to its legacy myeloma products.
The FDA granted accelerated approval to Replimune's TUDRIQEVTM (vusolimogene oderparepvec-wtpg) for melanoma treatment, reversing two earlier rejections following support from an advisory panel. The approval marks a significant turnaround for the biotech company after a tumultuous regulatory process.
The FDA has approved Novartis' radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for use in combination with hormone therapy for patients with PSMA-positive metastatic prostate cancer who are still hormone-sensitive, nearly doubling the eligible patient population from its previous indication for hormone-resistant cases.
Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.
The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.
AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer treatment Enhertu, which could provide access to women in England and Wales with HER2-low breast cancer.
Roche announced positive results from a head-to-head Phase 3 trial showing its KRAS G12C inhibitor divarasib demonstrated superior efficacy compared to competing treatments from Amgen and Bristol Myers Squibb in patients with KRAS-driven lung cancer.
The U.S. FDA has approved Orca Bio's TREGZI, the first precision-engineered cell therapy for allogeneic transplants in adults with hematological malignancies, designed to reduce stem cell transplant complications.
The EPCORE DLBCL-4 Phase 3 trial showed that epcoritamab (Epkinly) combined with lenalidomide significantly improved progression-free survival compared to R-GemOx chemotherapy in adults with relapsed or refractory diffuse large B-cell lymphoma who received at least one prior line of therapy. The results bring the bispecific antibody closer to a potential label expansion.
The FDA approved sacituzumab govitecan-hziy (Trodelvy) on June 24, 2026, for two indications in adults with triple-negative breast cancer: as monotherapy and in combination with pembrolizumab (Keytruda) for first-line treatment of advanced disease, offering new options beyond standard chemotherapy.
The FDA has approved the combination of belzutifan (Welireg) and pembrolizumab (Keytruda) as adjuvant treatment for patients with clear cell renal cell carcinoma at high risk of recurrence following nephrectomy, based on data from the phase 3 LITESPARK-022 trial.
The first randomized phase 3 trial comparing radiation schedules found that delivering stereotactic radiation over three to five sessions after surgery significantly improved local control and reduced cancer recurrence at the surgical site for patients with large, resected brain metastases compared with single-fraction treatment.
The FDA has rejected RP1, a breakthrough melanoma treatment, twice despite its promise in treating skin cancer. The rejections have left medical professionals puzzled and concerned about implications for future drug approvals.
Global phase III TROPION-Breast02 trial led by National Cancer Centre Singapore shows datopotamab deruxtecan significantly improves survival outcomes in triple-negative breast cancer patients, representing a major breakthrough for this aggressive cancer type.
Researchers have developed artificial intelligence tools to support clinical decision-making in hematologic malignancies, including HemaGuide from German Cancer Research Center for treatment recommendations and AI applications in palliative oncology for symptom management and prognostication.
Biofrontera Inc. filed a supplemental New Drug Application with the FDA on November 28, 2025, seeking approval to treat superficial basal cell carcinoma with Ameluz photodynamic therapy. This represents the first Phase 3 PDT study in sBCC patients conducted in the United States.